Jasper Therapeutics develops briquilimab, a clinical-stage antibody therapy targeting KIT (CD117) for mast cell driven diseases including chronic spontaneous urticaria, chronic inducible urticaria and asthma. Company news centers on briquilimab clinical data from BEACON, open-label extension and ETESIAN studies, financial results and corporate updates, investor conference participation, financing activity and governance changes tied to its development strategy.
Jasper Therapeutics (Nasdaq: JSPR) has appointed Vishal Kapoor to its Board of Directors. Kapoor, a healthcare veteran, is currently a Partner at Avego Management and previously led the life sciences venture strategy at Amplitude Healthcare Acquisition Corp. He has significant experience in developing therapeutic assets in biotechnology, having worked with Iveric bio and Genentech. The company, well-funded from a recent public offering, aims to advance its lead candidate, briquilimab, targeting c-Kit for chronic diseases and as a conditioning agent for stem cell transplants. The appointment is expected to enhance Jasper's strategic direction.
Jasper Therapeutics (Nasdaq: JSPR) announced promising results from a Phase 1/2 study of briquilimab as a conditioning agent for patients with Fanconi Anemia. Both patients exhibited successful neutrophil engraftment within 11 days, achieving 100% donor chimerism after six and three months, respectively. Briquilimab showed no treatment-related adverse events and was cleared by day 9 post-dosing. The study aims to reduce toxicity associated with traditional conditioning therapies like busulfan chemotherapy.
This update enhances confidence in briquilimab's potential to treat various patient groups effectively.
Jasper Therapeutics (Nasdaq: JSPR) announced promising Phase 1 results for briquilimab in treating acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) at the 2023 Tandem Meetings. Key findings show that all 12 AML patients achieved successful neutrophil engraftment, with a median recovery time of 19 days. Notably, 67% of patients remain free from relapse, and the conditioning regimen demonstrated a favorable safety profile with no significant adverse events. Additionally, the outpatient treatment model potentially reduces the clinical and economic burden of stem cell transplants.
Jasper Therapeutics presented promising data for its briquilimab treatment for sickle cell disease at the 2023 Transplantation & Cellular Therapy Meetings. The first two participants achieved 100% donor myeloid chimerism by Day 100, while a third participant reached this milestone by Day 30. Notably, all participants showed increased hemoglobin levels at their most recent follow-up, with values reaching 12.6 g/dL, 11.4 g/dL, and 14 g/dL. These findings, presented by Dr. John F. Tisdale, highlight the potential of briquilimab as a conditioning agent in stem cell transplants, indicating a significant step forward in addressing unmet needs in sickle cell disease treatment.
On February 2, 2023, Jasper Therapeutics (Nasdaq: JSPR) granted Ronald Martell, its President and CEO, a True-Up Option to purchase 1,093,831 shares of common stock. This option was granted after Jasper closed a public offering raising approximately $103.5 million on January 27, 2023. The True-Up Option has an exercise price of $1.78 per share and will vest over four years. Jasper, focused on novel antibody therapies targeting c-Kit for conditions like chronic spontaneous urticaria and myelodysplastic syndromes, aims to advance briquilimab as a therapeutic agent. The grant complies with Nasdaq Listing Rule 5635(c)(4), reflecting Jasper's commitment to employee incentive plans.
Jasper Therapeutics will host a corporate update conference call on January 31, 2023, from 8:30 am – 9:30 am Eastern Time. The call will be led by the management team and can be accessed by phone or through a live webcast available on their investor relations website. Jasper is focused on developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) for conditions such as chronic spontaneous urticaria and myelodysplastic syndromes (MDS). To date, the drug has shown safety and efficacy in over 130 participants. A replay of the webcast will be available for 90 days.
Jasper Therapeutics, Inc. (Nasdaq: JSPR) has successfully completed a public offering of 69 million shares at $1.50 per share, raising approximately $103.5 million. The offering price includes an additional 9 million shares purchased by underwriters. Proceeds will support the development of briquilimab, a monoclonal antibody targeting c-Kit, aimed at treating chronic urticaria and myelodysplastic syndromes (MDS), along with potential use in stem cell transplant conditioning. Credit Suisse and William Blair served as book-running managers for the offering, which was run under an effective registration statement with the SEC.
Jasper Therapeutics, Inc. (Nasdaq: JSPR) has priced its underwritten public offering of 60,000,000 shares of common stock at $1.50 per share, raising approximately $90 million. The net proceeds are intended for general corporate purposes, including capital expenditures and working capital. The offering is set to close on January 27, 2023, subject to customary closing conditions. Additionally, underwriters have a 30-day option to purchase up to 9,000,000 shares at the public offering price. The offering is conducted under an effective shelf registration statement with the SEC.
Jasper Therapeutics (Nasdaq: JSPR) announced plans for an underwritten public offering of common stock, subject to market conditions. The company intends to give underwriters a 30-day option to purchase an additional 15% of the shares. All shares will be sold by Jasper, with the offering facilitated by Credit Suisse Securities and William Blair & Company as active managers. The shares will be offered under an effective shelf registration. Proceeds from the offering may support the company's development of briquilimab, a monoclonal antibody targeting c-Kit for various diseases and stem cell transplants.
Jasper Therapeutics (Nasdaq: JSPR) announced positive data regarding its investigational monoclonal antibody, briquilimab (formerly JSP191), at the 2023 ASTCT Meetings. Three abstracts highlighted the safety and efficacy of briquilimab combined with low-dose radiation for treating older adults (median age 70) with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Key findings include durable remission in 8 of 12 AML patients after one year, lower than expected rates of graft-versus-host disease (GVHD) in 29 patients, and potential cost savings from outpatient procedures. These data support briquilimab's role in improving stem cell transplant safety and efficacy.